European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

Novo Holdings planned $16.5 billion purchase of Catalent (NYSE:CTLT) is being probed by the European antitrust regulator. The European Commission has set a date of Dec. 6 to decide if its analysis of ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall ...

Catalent is an attractive buyout target for Novo Holdings — which owns 77% of the voting shares in the drugmaker — because it is currently a subcontractor that helps manufacture Wegovy ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Bagsværd, Denmark, 8 November 2024 - Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of ...

European Union seeks input from rival pharmaceutical firms on Novo Holding $16.5 billion acquisition of Catalent.

Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S.